Roche's Atezolizumab Gets CDF Place For Bladder Cancer
Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.
You may also be interested in...
Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route.
The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.
A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.